+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Binge Eating Disorder Market Size and Share Outlook - Forecast Trends and Growth Analysis Report (2025-2034)

  • PDF Icon

    Report

  • 400 Pages
  • June 2025
  • Region: Global
  • Expert Market Research
  • ID: 5805735
The binge eating disorder market was valued at USD 0.81 Billion in 2024 driven by increasing awareness, advancements in treatment options, and the rising prevalence of the disorder across the 8 major markets. It is expected to grow at a CAGR of 6.00% during the forecast period 2025-2034 and attain a market value of USD 1.45 Billion by 2034.

Binge Eating Disorder Market Overview

Binge eating disorder (BED) is characterized by excessive eating within a short period, without engaging in purging behaviors such as vomiting. It can result in obesity, heart disease, and emotional problems. BED is the result of a combination of genetic, psychological, and environmental factors such as genetics, lack of self-confidence, and societal influences. Binge episodes can be exacerbated by stress and negative emotions.

Genetic factors, hormonal imbalances, and dopamine are all factors that influence the development and severity of the disorder. Mental health problems such as depression, anxiety, and previous trauma can lead to episodes of binge eating, along with emotional stressors. Societal expectations, limited eating habits, and genetic predisposition for eating disorders may elevate the chances of developing one.

Binge eating disorder treatment typically includes a mix of counseling, drugs, and adjustments in lifestyle. Cognitive behavioral therapy (CBT) is successful in handling triggers, while drugs such as lisdexamfetamine and antidepressants aid in diminishing cravings and balancing mood.

Binge Eating Disorder Market Growth Drivers

Increasing Prevalence of Binge Eating Disorder Spurs Market Growth

The rising occurrence of binge eating disorder is driving the growth of the market as awareness of mental health increases. As per the Eating Recovery Center’s eating disorder statistics for 2024, 28.8 million Americans, or 9% of the U.S. population, will experience an eating disorder at some point in their lives. Each year, 10,200 deaths occur due to eating disorders, resulting in one death every 52 minutes. Urbanization, inactive lifestyles, and high-stress levels lead to a rise in BED cases, particularly in developed areas.

Growing Awareness and Diagnosis to Meet Rising Binge Eating Disorder Market Demand

Efforts in public health campaigns and education have contributed to raising awareness of BED as a significant mental health condition. During the National Eating Disorders Awareness Week in February 2024, Monte Nido & Affiliates conducted an educative session on binge eating disorder. As a leading eating disorder treatment provider in the United States, they offer vital resources and expanded virtual treatment programs in 28 states. Their specialty program addresses core features of shame, guilt, and self-blame associated with binge eating disorder, encouraging individuals to seek help for mental health issues without fear of judgment has led to an increase in early diagnoses. Healthcare providers have improved their skills in recognizing BED, resulting in an increased need for treatment choices.

Binge Eating Disorder Market Trends

The market is witnessing several trends and developments to improve the current scenario. Some of the notable trends are as follows:

Advances in Treatments

Progress in treatments is leading to a rise in the need for medication-based therapies that focus on the neurological and psychological components of BED. Continued studies on novel drugs are expanding the range of treatment options, as pharmaceutical companies are funding clinical trials to create better treatments with reduced side effects. This is helping to tailor treatment plans to individuals and maintain market growth for treatments of BED.

Rising Use of Non-Invasive Therapies to Boost Binge Eating Disorder Market Value

Non-intrusive treatments like cognitive behavioral therapy (CBT) are gaining popularity for addressing BED. These treatments concentrate on altering eating habits and emotional cues without requiring invasive techniques. Treatment plans also incorporate group therapy, family counseling, and nutritional education among others.

Rising Focus on Mental Health in Corporate Wellness Programs

The increasing focus on mental health in company wellness initiatives is resulting in the inclusion of resources for the condition. Businesses are broadening their benefits packages to incorporate therapy, counseling, and stress management initiatives to tackle the consequences of untreated binge eating disorders. Educational workshops on eating disorders are being integrated to increase awareness and encourage early intervention.

Use of Digital Therapeutics

Digital therapeutics are influencing the treatment of BED by providing accessible resources such as mobile apps and online platforms for self-directed programs and cognitive behavioral therapy. These electronic tools enable people to monitor their symptoms in real-time and get remote assistance via telehealth services, especially helping younger patients and those in disadvantaged regions. The demand for digital therapeutics in treating BED is rising due to their cost efficiency and effectiveness.

Binge Eating Disorder Market Segmentation

The report titled “Binge Eating Disorder Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Drug Class

  • Antidepressant
  • Anticonvulsant
  • Anti-obesity Medication
  • Others

Market Breakup by Route of Administration

  • Oral
  • Parenteral
  • Others

Market Breakup by Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Market Breakup by Region

  • United States
  • EU-4 and the United Kingdom
  • Japan
  • India

Binge Eating Disorder Market Share

Market Share Based on Route of Administration to Witness Substantial Growth

Based on the route of administration, the market is divided into oral, parenteral, and others. The most frequent administration is through oral administration, where drugs such as lisdexamfetamine and antidepressants can be easily included in daily schedules. Oral medications allow for flexibility in dosage and self-administration, increasing accessibility and affordability for long-term treatment.

Binge Eating Disorder Market Analysis by Region

Based on region, the market report covers the United States, EU-4 (Germany, France, Italy, Spain), United Kingdom, Japan, and India.

The United States is expected to dominate the market because of the high prevalence of the disorder and the availability of advanced treatment options, along with extensive awareness initiatives and strong healthcare facilities encouraging treatment acceptance. Drugs such as lisdexamfetamine and treatments like CBT are frequently utilized, supported by insurance and government efforts.

There has been a significant increase in market growth in the EU-4 countries and the United Kingdom due to the rising awareness of eating disorders as serious health issues, leading to more investment in mental health services and a higher demand for treatments. The market in Japan and India is rapidly expanding driven by greater awareness, diagnosis rates,h ealthcare infrastructure enhancements, lifestyle modifications, urbanization, and stress.

Leading Players in the Binge Eating Disorder Market

The key features of the market report include patent analysis, grant analysis, funding, and investment analysis, clinical trials analysis as well as strategic initiatives by the leading players. The major companies in the market are as follows:

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is a biopharmaceutical company dedicated to creating new treatments for central nervous system disorders, immunology conditions, infectious diseases, and rare diseases. In July 2023, they started enrolling participants in the MGH Phase 2 'STROBE' Study of TNX-1900 (Intranasal Potentiated Oxytocin) for the treatment of binge-eating disorder in July 2023.

Chronos Therapeutics Limited

Chronos Therapeutics Ltd is a UK-based pharmaceutical company focused on developing drugs for neurodegenerative diseases. They are a major player in the binge eating disorder market, utilizing Orexin -1 Antagonist research for effective treatment with minimal side effects.

Pyramid Healthcare Inc.

Pyramid Healthcare offers a range of healthcare services in the United States, including residential and outpatient treatment, dual diagnosis, mental health, transitional housing, and specialty programs for substance abuse, mental health, autism, and eating disorders.

Eli Lilly and Company

Eli Lilly and Company in Indianapolis, Indiana is a healthcare company developing medications for various health conditions. The FDA approved Lilly's Zepbound (tirzepatide) in November 2023 for chronic weight management, providing a new treatment option for those struggling with obesity or being overweight with weight-related medical issues.

Other players in the market are Takeda Pharmaceutical Company Limited, VIVUS LLC, Sunovion Pharmaceuticals Inc., H. Lundbeck A/S, Orexigen Therapeutics Inc., Jazz Pharmaceuticals Inc., and Novo Nordisk A/S.

Key Questions Answered in the Binge Eating Disorder Market Report

  • What was the binge eating disorder market value in 2024?
  • What is the binge eating disorder market forecast outlook for 2025-2034?
  • What are the regional markets covered in the report?
  • What is the market segmentation based on drug class?
  • What is the market segmentation based on the route of administration?
  • What is the market breakup based on distribution channels?
  • What are the major factors aiding the binge eating disorder market demand?
  • How has the market performed so far and how is it anticipated to perform in the coming years?
  • What are the major drivers, opportunities, and restraints in the market?
  • What are the major trends influencing the market?
  • Which regional market is expected to dominate the market share in the forecast period?
  • Which country is likely to experience elevated growth during the forecast period?
  • Who are the key players involved in the binge eating disorder market?
  • What are the current unmet needs and challenges in the market?
  • How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?

This product will be delivered within 3-5 business days.

Table of Contents

1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Binge Eating Disorder Market Overview: 8 Major Market
3.1 Binge Eating Disorder Market Historical Value (2018-2024)
3.2 Binge Eating Disorder Market Forecast Value (2025-2034)
4 Vendor Positioning Analysis
4.1 Key Vendors
4.2 Prospective Leaders
4.3 Niche Leaders
4.4 Disruptors
5 Binge Eating Disorder: Disease Overview
5.1 Guidelines and Stages
5.2 Pathophysiology
5.3 Screening and Diagnosis
5.4 Therapy Pathway
6 Patient Profile
6.1 Patient Profile Overview
6.2 Patient Psychology and Emotional Impact Factors
6.3 Risk Assessment and Therapy Success Rate
7 Binge Eating Disorder Market Epidemiology Scenario and Forecast - 8 Major Markets
7.1 8MM Epidemiology Scenario Overview (2018-2034)
7.1.1 Prevalence, by Country
7.1.1.1 U.S.
7.1.1.2 U.K.
7.1.1.3 EU4
7.1.1.4 India
7.1.1.5 Japan
7.1.2 Mortality by Country
7.1.2.1 U.S.
7.1.2.2 U.K.
7.1.2.3 EU4
7.1.2.4 India
7.1.2.5 Japan
7.1.3 Treatment Type Seeking Rate by Country
7.1.3.1 U.S.
7.1.3.2 U.K.
7.1.3.3 EU4
7.1.3.4 India
7.1.3.5 Japan
8 Binge Eating Disorder Market Landscape: 8 Major Market*
8.1 Binge Eating Disorder Market: Developers Landscape
8.1.1 Analysis by Year of Establishment
8.1.2 Analysis by Company Size
8.1.3 Analysis by Region
8.2 Binge Eating Disorder Market: Product Landscape
8.2.1 Analysis by Drug Class
8.2.2 Analysis by Route of Administration
9 Binge Eating Disorder Market Challenges and Unmet Needs
9.1 Therapy Pathway Challenges
9.2 Compliance and Drop-Out Analysis
9.3 Awareness and Prevention Gaps
10 Cost of Therapy
11 Binge Eating Disorder: Market Dynamics
11.1 Market Drivers and Constraints
11.2 SWOT Analysis
11.2.1 Strengths
11.2.2 Weaknesses
11.2.3 Opportunities
11.2.4 Threats
11.3 PESTEL Analysis
11.3.1 Political
11.3.2 Economic
11.3.3 Social
11.3.4 Technological
11.3.5 Legal
11.3.6 Environment
11.4 Porter’s Five Forces Model
11.4.1 Bargaining Power of Suppliers
11.4.2 Bargaining Power of Buyers
11.4.3 Threat of New Entrants
11.4.4 Threat of Substitutes
11.4.5 Degree of Rivalry
11.5 Key Demand Indicators
11.6 Key Price Indicators
11.7 Industry Events, Initiatives, and Trends
11.8 Value Chain Analysis
12 Binge Eating Disorder Market Segmentation: 8 Major Markets
12.1 Binge Eating Disorder Market by Drug Class
12.1.1 Market Overview
12.1.2 Antidepressant
12.1.3 Anticonvulsant
12.1.4 Anti-obesity Medication
12.1.5 Others
12.2 Binge Eating Disorder Market by Route of Administration
12.2.1 Market Overview
12.2.2 Oral
12.2.3 Parenteral
12.2.4 Others
12.3 Binge Eating Disorder Market by Distribution Channel
12.3.1 Market Overview
12.3.2 Hospital Pharmacy
12.3.3 Retail Pharmacy
12.3.4 Online Pharmacy
12.3.5 Others
12.4 Binge Eating Disorder Market by Region
12.4.1 Market Overview
12.4.2 United States
12.4.3 EU-4 and the United Kingdom
12.4.3.1 Germany
12.4.3.2 France
12.4.3.3 Italy
12.4.3.4 Spain
12.4.3.5 United Kingdom
12.4.4 Japan
12.4.5 India
13 United States Binge Eating Disorder Market (218-2034)
13.1 United States Binge Eating Disorder Market Historical Value (2018-2024)
13.2 United States Binge Eating Disorder Market Forecast Value (2025-2034)
13.3 United States Binge Eating Disorder Market by Drug Class
13.3.1 Market Overview
13.3.2 Antidepressant
13.3.3 Anticonvulsant
13.3.4 Anti-obesity Medication
13.3.5 Others
13.4 United States Binge Eating Disorder Market by Route of Administration
13.4.1 Market Overview
13.4.2 Oral
13.4.3 Parenteral
13.4.4 Others
13.5 United States Binge Eating Disorder Market by Distribution Channel
13.5.1 Market Overview
13.5.2 Hospital Pharmacy
13.5.3 Retail Pharmacy
13.5.4 Online Pharmacy
13.5.5 Others
14 EU-4 and United Kingdom Binge Eating Disorder Market (218-2034)
14.1 EU-4 and United Kingdom Binge Eating Disorder Market Historical Value (2018-2024)
14.2 EU-4 and United Kingdom Binge Eating Disorder Market Forecast Value (2025-2034)
14.3 EU-4 and United Kingdom Binge Eating Disorder Market by Drug Class
14.3.1 Market Overview
14.3.2 Antidepressant
14.3.3 Anticonvulsant
14.3.4 Anti-obesity Medication
14.3.5 Others
14.4 EU-4 and United Kingdom Binge Eating Disorder Market by Route of Administration
14.4.1 Market Overview
14.4.2 Oral
14.4.3 Parenteral
14.4.4 Others
14.5 EU-4 and United Kingdom Binge Eating Disorder Market by Distribution Channel
14.5.1 Market Overview
14.5.2 Hospital Pharmacy
14.5.3 Retail Pharmacy
14.5.4 Online Pharmacy
14.5.5 Others
15 Japan Binge Eating Disorder Market
15.1 Japan Binge Eating Disorder Market Historical Value (2018-2024)
15.2 Japan Binge Eating Disorder Market Forecast Value (2025-2034)
15.3 Japan Binge Eating Disorder Market by Drug Class
15.3.1 Market Overview
15.3.2 Antidepressant
15.3.3 Anticonvulsant
15.3.4 Anti-obesity Medication
15.3.5 Others
15.4 Japan Binge Eating Disorder Market by Route of Administration
15.4.1 Market Overview
15.4.2 Oral
15.4.3 Parenteral
15.4.4 Others
15.5 Japan Binge Eating Disorder Market by Distribution Channel
15.5.1 Market Overview
15.5.2 Hospital Pharmacy
15.5.3 Retail Pharmacy
15.5.4 Online Pharmacy
15.5.5 Others
16 India Binge Eating Disorder Market
16.1 India Binge Eating Disorder Market Historical Value (2018-2024)
16.2 India Binge Eating Disorder Market Forecast Value (2025-2034)
16.3 India Binge Eating Disorder Market by Drug Class
16.3.1 Market Overview
16.3.2 Antidepressant
16.3.3 Anticonvulsant
16.3.4 Anti-obesity Medication
16.3.5 Others
16.4 India Binge Eating Disorder Market by Route of Administration
16.4.1 Market Overview
16.4.2 Oral
16.4.3 Parenteral
16.4.4 Others
16.5 India Binge Eating Disorder Market by Distribution Channel
16.5.1 Market Overview
16.5.2 Hospital Pharmacy
16.5.3 Retail Pharmacy
16.5.4 Online Pharmacy
16.5.5 Others
17 Regulatory Framework
17.1 Regulatory Overview
17.2 US FDA
17.3 EU EMA
17.4 INDIA CDSCO
17.5 JAPAN PMDA
17.6 Others
18 Patent Analysis
18.1 Analysis by Type of Patent
18.2 Analysis by Publication Year
18.3 Analysis by Issuing Authority
18.4 Analysis by Patent Age
18.5 Analysis by CPC Analysis
18.6 Analysis by Patent Valuation
18.7 Analysis by Key Players
19 Clinical Trial Analysis
19.1 Analysis by Trial Registration Year
19.2 Analysis by Trial Status
19.3 Analysis by Trial Phase
19.4 Analysis by Therapeutic Area
19.5 Analysis by Geography
20 Grant Analysis
20.1 Analysis by Year
20.2 Analysis by Amount Awarded
20.3 Analysis by Issuing Authority
20.4 Analysis by Grant Product
20.5 Analysis by Funding Institute
20.6 Analysis by Departments
20.7 Analysis by Recipient Organization
21 Funding and Investment Analysis
21.1 Analysis by Funding Instances
21.2 Analysis by Type of Funding
21.3 Analysis by Funding Amount
21.4 Analysis by Leading Players
21.5 Analysis by Leading Investors
21.6 Analysis by Geography
22 Strategic Initiatives
22.1 Analysis by Partnership Instances
22.2 Analysis by Type of Partnership
22.3 Analysis by Leading Players
22.4 Analysis by Geography
23 Supplier Landscape
23.1 Market Share by Top 5 Companies
23.2 Tonix Pharmaceuticals Holding Corp.
23.2.1 Financial Analysis
23.2.2 Product Portfolio
23.2.3 Demographic Reach and Achievements
23.2.4 Company News and Developments
23.2.5 Certifications
23.3 Takeda Pharmaceutical Company Limited
23.3.1 Financial Analysis
23.3.2 Product Portfolio
23.3.3 Demographic Reach and Achievements
23.3.4 Company News and Developments
23.3.5 Certifications
23.4 Chronos Therapeutics Limited
23.4.1 Financial Analysis
23.4.2 Product Portfolio
23.4.3 Demographic Reach and Achievements
23.4.4 Company News and Developments
23.4.5 Certifications
23.5 Pyramid Healthcare Inc.
23.5.1 Financial Analysis
23.5.2 Product Portfolio
23.5.3 Demographic Reach and Achievements
23.5.4 Company News and Developments
23.5.5 Certifications
23.6 VIVUS LLC.
23.6.1 Financial Analysis
23.6.2 Product Portfolio
23.6.3 Demographic Reach and Achievements
23.6.4 Company News and Developments
23.6.5 Certifications
23.7 Sunovion Pharmaceuticals Inc.
23.7.1 Financial Analysis
23.7.2 Product Portfolio
23.7.3 Demographic Reach and Achievements
23.7.4 Company News and Developments
23.7.5 Certifications
23.8 H. Lundbeck A/S
23.8.1 Financial Analysis
23.8.2 Product Portfolio
23.8.3 Demographic Reach and Achievements
23.8.4 Company News and Developments
23.8.5 Certifications
23.9 Orexigen Therapeutics, Inc
23.9.1 Financial Analysis
23.9.2 Product Portfolio
23.9.3 Demographic Reach and Achievements
23.9.4 Company News and Developments
23.9.5 Certifications
23.10 Novo Nordisk A/S
23.10.1 Financial Analysis
23.10.2 Product Portfolio
23.10.3 Demographic Reach and Achievements
23.10.4 Company News and Developments
23.10.5 Certifications
23.11 Eli Lily and Company
23.11.1 Financial Analysis
23.11.2 Product Portfolio
23.11.3 Demographic Reach and Achievements
23.11.4 Company News and Developments
23.11.5 Certifications
23.12 Jazz Pharmaceuticals Inc.
23.12.1 Financial Analysis
23.12.2 Product Portfolio
23.12.3 Demographic Reach and Achievements
23.12.4 Company News and Developments
23.12.5 Certifications
24 Binge Eating Disorder Market - Distribution Model (Additional Insight)
24.1 Overview
24.2 Potential Distributors
24.3 Key Parameters for Distribution Partner Assessment
25 Key Opinion Leaders (KOL) Insights (Additional Insight)
26 Payment Methods (Additional Insight)
26.1 Government Funded
26.2 Private Insurance
26.3 Out-of-Pocket

Companies Mentioned

  • Tonix Pharmaceuticals Holding Corp
  • Chronos Therapeutics Limited
  • Pyramid Healthcare Inc.
  • Eli Lilly and Company

Table Information